| [1] |
McGregor MM, Nelson AB. Circuit mechanisms of Parkinson's disease[J]. Neuron, 2019, 101(6): 1042-56. doi:10.1016/j.neuron.2019.03.004
|
| [2] |
Qi SG, Yin P, Wang LH, et al. Prevalence of Parkinson's disease: a community-based study in China[J]. Mov Disord, 2021, 36(12): 2940-4. doi:10.1002/mds.28762
|
| [3] |
Zhu JQ, Cui YS, Zhang JJ, et al. Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis[J]. Lancet Healthy Longev, 2024, 5(7): e464-79. doi:10.1016/s2666-7568(24)00094-1
|
| [4] |
Peng SY, Liu P, Wang XW, et al. Global, regional and national burden of Parkinson's disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991-2021[J]. BMC Neurol, 2025, 25(1): 178. doi:10.1186/s12883-025-04191-8
|
| [5] |
Wilson DM 3rd, Cookson MR, Van Den Bosch L, et al. Hallmarks of neurodegenerative diseases[J]. Cell, 2023, 186(4): 693-714. doi:10.1016/j.cell.2022.12.032
|
| [6] |
Leite Silva ABR, Gonçalves de Oliveira RW, Diógenes GP, et al. Premotor, nonmotor and motor symptoms of Parkinson's disease: a new clinical state of the art[J]. Ageing Res Rev, 2023, 84: 101834. doi:10.1016/j.arr.2022.101834
|
| [7] |
Ahmad MH, Rizvi MA, Ali M, et al. Neurobiology of depression in Parkinson's disease: insights into epidemiology, molecular mechanisms and treatment strategies[J]. Ageing Res Rev, 2023, 85: 101840. doi:10.1016/j.arr.2022.101840
|
| [8] |
Morris HR, Spillantini MG, Sue CM, et al. The pathogenesis of Parkinson's disease[J]. Lancet, 2024, 403(10423): 293-304. doi:10.1016/s0140-6736(23)01478-2
|
| [9] |
Ye H, Robak LA, Yu MG, et al. Genetics and pathogenesis of Parkinson's syndrome[J]. Annu Rev Pathol, 2023, 18: 95-121. doi:10.1146/annurev-pathmechdis-031521-034145
|
| [10] |
Tang LL, Chen C, Xia BM, et al. Effect of Wenshen-yanggan decoction on movement disorder and substantia nigra dopaminergic neurons in mice with chronic Parkinson's disease[J]. Evid Based Complement Alternat Med, 2020, 2020: 9838295. doi:10.1155/2020/9838295
|
| [11] |
吴天晨, 梁 艳, 邹丽萍. 温肾养肝方治疗帕金森病流涎及相关非运动症状临床观察[J]. 山西中医, 2023, 39(6): 30-3. doi:10.20002/j.issn.1000-7156.2023.06.011
|
| [12] |
Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease[J]. Nat Protoc, 2007, 2(1): 141-51. doi:10.1038/nprot.2006.342
|
| [13] |
赵 杨. 赵杨效方治验: 温肾养肝汤[J]. 江苏中医药, 2022, 54(5): 12-3. doi:10.19844/j.cnki.1672-397X.2022.05.003
|
| [14] |
Cheng N, Wang H, Hao HF, et al. Research progress on polysaccharide components of Cistanche deserticola as potential pharmaceutical agents[J]. Eur J Med Chem, 2023, 245(Pt 1): 114892. doi:10.1016/j.ejmech.2022.114892
|
| [15] |
段晓宇, 范 飒, 祝康杰, 等. 松果菊苷对便秘小鼠的通便作用及其机制[J]. 中成药, 2024, 46(4): 1162-7. doi:10.3969/j.issn.1001-1528.2024.04.014
|
| [16] |
Luo X, Wang XJ, Huang SW, et al. Paeoniflorin ameliorates experimental colitis by inhibiting gram-positive bacteria-dependent MDP-NOD2 pathway[J]. Int Immunopharmacol, 2021, 90: 107224. doi:10.1016/j.intimp.2020.107224
|
| [17] |
Ma YJ, Lang XM, Yang Q, et al. Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis[J]. Int Immunopharmacol, 2023, 119: 110247. doi:10.1016/j.intimp.2023.110247
|
| [18] |
张国欣, 陈也佳, 王 淼, 等. 基于16S rDNA研究钩藤碱对自发性高血压大鼠肠道菌群的影响[J]. 中国临床药理学杂志, 2023, 39(1): 57-60. doi:10.13699/j.cnki.1001-6821.2023.01.012
|
| [19] |
Hou XZ, Liang XM, Zhao X, et al. Uncaria rhynchophylla alkaloid extract exerts neuroprotective activity against Parkinson's disease via activating mitophagy with the involvement of UCHL1[J]. J Ethnopharmacol, 2025, 338(Pt 1): 119009. doi:10.1016/j.jep.2024.119009
|
| [20] |
Ou ZM, You Y, Yi H, et al. Key lipoprotein receptor targeted echinacoside-liposomes effective against Parkinson's disease in mice model[J]. Int J Nanomedicine, 2024, 19: 8463-83. doi:10.2147/ijn.s468942
|
| [21] |
Stoll AC, Kemp CJ, Patterson JR, et al. Neuroinflammatory gene expression profiles of reactive Glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions[J]. Neurobiol Dis, 2024, 191: 106411. doi:10.1016/j.nbd.2024.106411
|
| [22] |
Bloem BR, Okun MS, Klein C. Parkinson's disease[J]. Lancet, 2021, 397(10291): 2284-303. doi:10.1201/b12952-20
|
| [23] |
Guo Y, Yang JX, Liu YX, et al. Detection and assessment of Parkinson's disease based on gait analysis: a survey[J]. Front Aging Neurosci, 2022, 14: 916971. doi:10.3389/fnagi.2022.916971
|
| [24] |
Nagatsu T. Catecholamines and Parkinson's disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview[J]. J Neural Transm (Vienna), 2024, 131(6): 617-30. doi:10.1007/s00702-023-02673-y
|
| [25] |
Nagatsu T, Nakashima A, Watanabe H, et al. Neuromelanin in Parkinson's disease: tyrosine hydroxylase and tyrosinase[J]. Int J Mol Sci, 2022, 23(8): 4176. doi:10.3390/ijms23084176
|
| [26] |
Socała K, Doboszewska U, Szopa A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders[J]. Pharmacol Res, 2021, 172: 105840. doi:10.1016/j.phrs.2021.105840
|
| [27] |
Zhang ZN, Hui Z, Chen C, et al. Neuroprotective effects and related mechanisms of echinacoside in MPTP-induced PD mice[J]. Neuropsychiatr Dis Treat, 2021, 17: 1779-92. doi:10.2147/ndt.s299685
|
| [28] |
Brown EM, Clardy J, Xavier RJ. Gut microbiome lipid metabolism and its impact on host physiology[J]. Cell Host Microbe, 2023, 31(2): 173-86. doi:10.1016/j.chom.2023.01.009
|
| [29] |
Mahbub NU, Islam MM, Hong ST, et al. Dysbiosis of the gut microbiota and its effect on α‑synuclein and prion protein misfolding: consequences for neurodegeneration[J]. Front Cell Infect Microbiol, 2024, 14: 1348279. doi:10.3389/fcimb.2024.1348279
|
| [30] |
Agirman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis[J]. Science, 2021, 374(6571): 1087-92. doi:10.1126/science.abi6087
|
| [31] |
Kuo WT, Odenwald MA, Turner JR, et al. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival[J]. Ann N Y Acad Sci, 2022, 1514(1): 21-33. doi:10.1111/nyas.14798
|
| [32] |
Guo YY, Liu ML, He XD, et al. Functional changes of intestinal mucosal barrier in surgically critical patients[J]. World J Emerg Med, 2010, 1(3): 205-8.
|
| [33] |
Zhang ZJ, Li H, Su YF, et al. Neuroprotective effects of a cholecystokinin analogue in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Parkinson's disease mouse model[J]. Front Neurosci, 2022, 16: 814430. doi:10.3389/fnins.2022.814430
|
| [34] |
Wu HJ, Zheng JW, Xu SB, et al. Mer regulates microglial/macrophage M1/M2 polarization and alleviates neuroinflammation following traumatic brain injury[J]. J Neuroinflammation, 2021, 18(1): 2. doi:10.1186/s12974-020-02041-7
|
| [35] |
Wang JJ, Pan HJ, Lin ZY, et al. Neuroprotective effect of fractalkine on radiation-induced brain injury through promoting the M2 polarization of microglia[J]. Mol Neurobiol, 2021, 58(3): 1074-87. doi:10.1007/s12035-020-02138-3
|
| [36] |
Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration[J]. Nat Rev Neurol, 2023, 19(7): 395-409. doi:10.1038/s41582-023-00822-1
|
| [37] |
Korkmaz OT, Tunçel N. Advantages of vasoactive intestinal peptide for the future treatment of Parkinson's disease[J]. Curr Pharm Des, 2018, 24(39): 4693-701. doi:10.2174/1381612825666190111150953
|
| [38] |
Isik S, Yeman Kiyak B, Akbayir R, et al. Microglia mediated neuroinflammation in Parkinson's disease[J]. Cells, 2023, 12(7): 1012. doi:10.3390/cells12071012
|